Compare Core Scientific Inc (CORZ) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Moderna, Inc. — how do they compare? Core Scientific Inc trades at $15.26 (market cap $4.94B), while Moderna, Inc. trades at $206.43 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 15.9× Core Scientific Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Moderna, Inc. for 59 Days on average.
| CORZ | MRNA | |
|---|---|---|
Market Cap | $4.94B | $78.65B |
Volume | 15,630,800 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $29.16 | $203.46 |
52-Week Low | $13.57 | $22.36 |
Typical Hold Time | 20 Days | 59 Days |
Enterprise Value | $7.46B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORZ trades at $15.94, down 4.44% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $288.62 million in 2025, with a negative net income margin of -324.9% in 2026. Recent news highlights its pivot to AI data center hosting and executive appointments, while analyst consensus remains strongly bullish with an 86.36% buy rating.
The outlook is mixed: strong analyst support and AI infrastructure growth offer upside potential, but persistent losses, high cash burn, and competitive pressures pose significant risks. Investors face volatility from execution challenges in the capital-intensive data center transition.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
